Company ProfilePremium

Green Biologics Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Green Biologics Limited - Company showcase

Year Founded & Workforce

2003

Green Biologics Limited logo

Green Biologics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Green Biologics Limited Overview

Green Biologics Limited was an Oxfordshire-based industrial biotechnology company that set out to revive acetone-butanol-ethanol (ABE) fermentation — a Clostridium-based process that had been displaced by petrochemical routes by the 1960s — using genetically improved solventogenic Clostridium strains and modern process engineering. Its thesis was that bio-based n-butanol and acetone could command premiums over petroleum equivalents in coatings, personal care, cleaning and consumer products, and that idle first-generation US corn-ethanol plants could be retrofitted cheaply to produce them. Backed by Sofinnova Partners, Swire Pacific, Capricorn, Oxford Capital and Morningside, it acquired and converted the 21-million-gallon Central Minnesota Ethanol Co-op plant, shipping commercially from late 2016 under the BioPure brand. Unable to reach cash break-even against petrochemical pricing, it closed the plant in July 2019. The UK parent pivoted to recombinant protein expression as Biocleave, before the legacy entity was struck off in December 2025.


What the company did

Across its 23-year legal life the entity passed through four distinct business models:

  1. Integrated renewable chemicals producer (2014–2019). Through Green Biologics, Inc. and Central MN Renewables LLC, the group owned and operated a retrofitted corn-ethanol plant in Little Falls, Minnesota, producing bio-based n-butanol and acetone and marketing them, plus derivatives, into specialty chemicals and consumer-product supply chains.

  2. Specialty biologics / protein expression (2019–2023, as Biocleave Limited). After the US closure, the UK parent changed its name to Biocleave and redeployed its CRISPR-based CLEAVE™ genome-editing toolkit to engineer Clostridium as a Gram-positive, endotoxin-free host for recombinant protein expression, supplying research reagents and contract expression services.

  3. Non-trading shell (Aug 2023 – Dec 2025). After reverting to the Green Biologics name, the entity was classified as non-trading, moved its registered office to Wargrave, filed small-company accounts and was voluntarily struck off. The Biocleave operating business is understood to continue under BCL2020 Ltd (trading as biocleave).

Company's own description

The company described its Clostridium fermentation platform as converting a wide range of sustainable feedstocks into high-performance green chemicals — n-butanol, acetone and, via chemical synthesis, their derivatives — sold to a growing global customer base (2015 financing announcement). Its later tagline described renewable chemicals naturally designed to deliver performance that adds value to everyday products. No annual-report "business description" from a listed-company filing exists. In its Biocleave phase, the CEO described the business as still using solventogenic clostridia but applying CLEAVE™ genome editing to generate recombinant strains making higher-value products at much lower volumes (Microbiology Society interview, Oct 2020).

Revenue model

Revenue streamEraNatureDisclosure
Bulk/specialty chemical sales (n-butanol, acetone)2016–2019Product sales, B2B, domestic and exportAmounts not publicly disclosed
Derivative products (bio-IPA, butyl/isopropyl esters)2016–2019Product sales, partly via partner synthesis—
Formulated consumer-product ingredients (nail polish remover acetone, lighter fluid, dry-cleaning solvent)2018–2019Ingredient supply into partner brands / private label—
Fuel ethanolDec 2014 – c.2016Commodity product sales while the Little Falls plant continued to run as an ethanol plant pre-conversion—
Technology licensing / R&D services2003–2014 and Biocleave eraLicensing, grants, collaborative R&D—
Recombinant protein reagents and expression services2020–2023 (entity); continuing in successorCatalogue products via distributors plus contract servicesNot publicly disclosed; Preqin reports USD 0 revenue for 2022 at entity level

Value-chain position and customers

In its operating peak, GBL sat at the midstream conversion stage: it bought US corn (the Little Falls plant historically consumed about 7.5 million bushels a year as an ethanol plant), fermented it to solvents, and sold molecules to formulators and brand owners. Customer types included coatings and adhesives manufacturers, personal-care contract formulators (Marianna Industries), retailers (Sally Beauty, via private label), consumer brands (Kingsford Charcoal) and specialty chemical firms (Kreussler for dry cleaning). End-markets cited for n-butanol at the time of the plant purchase were paints, coatings, adhesives, inks, plastics, pharmaceuticals, food ingredients, household cleaners and personal care.

Independent characterisation

Green Biologics is best understood as a capital-intensive industrial-biotech scale-up that failed on unit economics, not on technology. The company proved the process at commercial scale (commercial shipments from December 2016; USDA BioPreferred certification; Kosher and Halal certification; launch of several "world's first" bio-based consumer products) but could not close the cost gap with petrochemical acetone and oxo-butanol, which are low-cost by-products or high-scale products of integrated petrochemical chains. Its premium-niche strategy (consumer products where "bio-based" carries a price premium) generated launches but evidently not enough volume to fill a 21-million-gallon-equivalent plant before investors withdrew support in mid-2019. The Biocleave pivot was a classic "salvage the IP" strategy: re-deploy strain-engineering know-how into low-volume, high-value biologics.

Strategy

Historic strategic themes (operating era)

Retrofit, not greenfield: Management argued that converting a first-generation ethanol plant demonstrated a low-capex path to renewable chemicals; CMEC's CEO called the deal pioneering proof that such retrofits were possible (Brainerd Dispatch, Dec 2014).

Chemicals over fuels: The thesis, articulated at the 2013 plant deal, was that n-butanol as a chemical was worth more than double ethanol as a fuel, targeting buyers such as coatings and adhesives makers.

Premium "bio-based" positioning: USDA BioPreferred, Kosher/Halal certification, American Chemistry Council membership and Responsible Care alignment were used to differentiate from petrochemical commodities.

Downstream partnerships: Consumer launches with Kingsford, Kreussler and Marianna/Sally Beauty sought to capture brand premiums and build demand pull.

Biocleave strategy (2019–2023)

Redeploy CLEAVE™ strain engineering to make high-value, low-volume products — recombinant proteins, toxins and research reagents — exploiting Clostridium's Gram-positive, endotoxin-free profile and its tolerance of proteins toxic to E. coli. Commercial infrastructure included distributor agreements and standard terms (Harper James), academic placements (South Coast Biosciences DTP) and a KTP with Aston University on membrane-associated proteins.

Last 24 months (Oct 2024 – Oct 2026)

For the profiled legal entity, the only "initiative" in the last 24 months was its orderly closure: final accounts (Jul 2025), strike-off application (Sep 2025) and dissolution (Dec 2025). No medium-term financial targets, ESG commitments or cost programmes were published. Any current strategy belongs to the successor BCL2020 Ltd and is not publicly disclosed in sources reviewed.

Products & Services

Renewable chemicals (2016–2019)

ProductDescriptionKey specs/capabilitiesTarget customerLaunchPricing
BioPure n-butanol100% bio-based normal butanol from Clostridium fermentation of US cornUSDA Certified Biobased / BioPreferred; Kosher & Halal certified; drop-in replacement for petro n-butanolCoatings, adhesives, inks, plastics, pharma, food ingredients, cleaners, personal careCommercial shipments Dec 2016Not disclosed; positioned at premium to petro grade
BioPure acetone100% bio-based acetone, co-product of ABE fermentationUSDA BioPreferred; differentiated impurity profile cited by management as a performance benefitPersonal care (nail care), cleaning, solventsDec 2016—
Bio-based isopropyl alcohol (IPA)High-purity 100% bio-based IPA (via derivatisation of acetone)Listed in portfolio via own manufacturing and partner collaborationsPersonal care, cleaning, pharmac.2016–2017—
Specialty estersEsters of n-butanol, isopropanol and other bio-based alcoholsPartner-manufactured; solvent and fragrance applicationsCoatings, flavours & fragrances, cleaningc.2016–2017—
Fuel ethanolProduced at Little Falls (21 MMgy nameplate) pre-conversionCommodityFuel blendersDec 2014 – 2016Market price

Formulated / co-branded consumer applications (2018–2019)

ProductPartnerDescriptionLaunchNotes
Bio-based acetone nail polish remover ("Beauty Secrets")Marianna Industries (formulator, Omaha, NE); Sally Beauty (retailer)Billed as the world's first plant-derived acetone nail polish remover; 100% USDA BioPreferred25 Jun 2018Carried in over 3,000 Sally Beauty stores; offered for further private-label/branded deals
EcoLight natural charcoal lighter fluidKingsford CharcoalBio-based lighter fluid using GBL solventsJan–Mar 2018Consumer retail via Kingsford
Bio-based dry-cleaning solventKreussler (Florida-based)Corn-based dry-cleaning solventAnnounced Apr 2018Production collaboration

Technology platform

PlatformDescriptionStatus
Solventogenic Clostridium strainsProprietary improved strains producing acetone and n-butanol from sugarsProven at commercial scale 2016–2019
Advanced fermentation / retrofit processProcess to retrofit first-generation dry-mill ethanol plants to ABE productionDeployed at Little Falls
CLEAVE™Patented CRISPR-based genome-editing technology for Clostridium enabling stable SNPs, insertions and deletionsCarried into Biocleave

Biocleave-era offerings (2020–2023 at entity; continuing in successor)

OfferingDescriptionTarget customerNotes
Clostridium recombinant protein expression serviceGram-positive host lacking lipopolysaccharide; endotoxin levels reported below 0.005 EU per µgLife-science researchers, therapeutics, agritech, flavour & fragranceContract service model
Catalogue reagentsBacterial toxins and toxin fragments (safely expressed in Clostridium), protozoal, clostridial and cancer-research proteins including PARPsAcademic and pharma researchSold directly and via distributors (agreements drafted with Harper James)
Membrane-associated protein expressionCapability under development via Knowledge Transfer Partnership with Aston UniversityPharma researchRun through BCL2020 Ltd

Financial Narrative

Data availability

The entity filed group accounts for FY2019 and FY2020, and small-company "total exemption full" accounts for FY2021–FY2025. Fiscal years end 30 June.

Income statement

Note: dividends are shown as zero on the basis that a loss-making venture-funded company with accumulated deficits cannot lawfully distribute under UK company law; no dividend has ever been reported. The Preqin EBITDA figure (USD -33,282) and Craft EBIT (GBP -25.0K) are broadly consistent once currency conversion is considered (c.GBP 25K ≈ USD 31–33K at 2022 rates). Margins and revenue CAGR are not computable.

Share capital (from statutory filings)

The FY2019 column reflects the statement of capital at 9 Nov 2018 (second-filed SH06) and the FY2020 column the statement at 26 Sep 2019; both relate to share cancellations around the investor exit and recapitalisation. A senior convertible loan was approved by resolution dated 26 Aug 2019.

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not publicly disclosed and cannot be computed from the verified data.

Historical capital raised (operating era)

Commentary. The financial story is one of heavy, front-loaded capital consumption (over USD 100M from late 2013 to 2015 alone) to acquire and retrofit a commodity-scale plant, followed by a revenue ramp that never reached break-even. The capitalisation table shows the 2018 investor-director exits (Sofinnova, Capricorn, Oxford Capital in October–November 2018, Swire in January 2019) foreshadowing the July 2019 withdrawal of financial support. Post-2019 the legal entity became financially immaterial: by FY2022 it reported essentially nil revenue, a c.GBP 25K loss and c.GBP 51K cash, consistent with a holding/shell role while operations migrated to the successor. The FY2023–FY2025 total-exemption accounts and the 2025 strike-off application confirm the entity had no material assets or liabilities at the end (a DS01 can only be filed by a company that has not traded in the prior three months and has no outstanding creditor issues it is aware of).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRoleStatus

Green Biologics Limited (04358718)

England & Wales

Group parent; UK R&D labs (Milton Park, Abingdon); strain development

Renamed Biocleave 2019; reverted name 2023; dissolved 16 Dec 2025

Green Biologics, Inc.

USA (Ohio-based)

US operating company; sales & marketing (Medina, OH); earlier Gahanna/Columbus, OH

—

Central MN Renewables LLC

USA (Minnesota)

Owner/operator of Little Falls plant; held rolled-over CMEC member equity/debt

—

BCL2020 Ltd (trading as "biocleave")

England & Wales (presumed)

Successor protein-expression business

Active per Aston University KTP documentation; relationship to 04358718 inferred, not confirmed by filings reviewed

Segment Revenue

Segment (analytical)FY2017FY2018FY2019

Segment (analytical)

FY2021

FY2022

FY2023

Protein expression / Biocleave revenue at entity level (USD Mn)

—0—

Income Statement and Income Statement (USD)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (USD, Preqin)

—0———

Operating income / EBIT (GBP Mn, Craft)

—-0.025———

EBITDA (USD, Preqin)

—-33,282———

Net income (GBP Mn, Craft)

—-0.025———

Dividends per share (GBP)

00000

Key Financials

MetricFY2022

Cash and equivalents (GBP Mn, Craft)

0.051

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (GBP Mn)

00000

Key Financials (GBP)

MetricFY2019FY2020

Issued share capital nominal value after cancellations (GBP)

15,239.9013,871.06

Round Details

RoundDateAmountLead / participantsSource

Seed rounds

Pre-2010

c.GBP 0.37M combined

Not specified

Unquote

Series A-type

May 2010

GBP 4.9M

Oxford Capital Partners, Capricorn Venture Partners, Carbon Trust, Morningside

Unquote

Series B

Dec 2013

USD 25M (GBP 15.4M)

Sofinnova Partners, Swire Pacific (board seats from Nov 2013)

Unquote; Business Magazine

Follow-on equity

2015

USD 42M

Co-led by Swire Pacific and Sofinnova; Capricorn, Oxford Capital, Morningside, ConvergInce Holdings participated

Business Magazine

Debt and rollover

2015

USD 34M

Predominantly Tennenbaum Capital Partners debt; plus CMEC members' rolled equity/debt in Central MN Renewables

Business Magazine

Total (aggregator)

2003–2019

USD 139.5M

—

Crunchbase via StartupBlink

Biocleave-era (aggregator)

2019–2023

USD 2.69M

Not specified

PitchBook

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable — never listed

Dividend history

None paid

Buyback authorisations

None; share cancellations in 2018–2019 relate to restructuring

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

Not publicly disclosed; 2015 Tennenbaum debt and 2019 senior convertible loan known to have existed

Balance Sheet

MetricFY2014FY2016

Equity raised (USD Mn)

2542

Debt and rolled-over funding raised (USD Mn)

—34

Analyst Conclusions

Management guidance / consensus. None. The profiled entity is dissolved; there is no guidance, consensus or forward outlook. The relevant forward-looking question concerns the successor (BCL2020 Ltd, trading as biocleave), for which no financial disclosures were located.

Bull-case arguments (for the technology/successor)

  1. Proven platform: the team took ABE fermentation to commercial scale in 2016 and holds patented CLEAVE™ editing — a rare depth of Clostridium know-how.

  2. Differentiated expression niche: sub-0.005 EU/µg endotoxin and toxin tolerance create a defensible technical niche against E. coli-based suppliers.

  3. Capital-light model: reagents and services require far less capital than the 21 MMgy plant that sank the original business.

Bear-case arguments

  1. Entity extinct: Green Biologics Limited was dissolved on 16 Dec 2025; there is no investable or contractable entity under this name.

  2. Track record of cash burn: over USD 100M raised without reaching break-even; the 2019 closure crystallised investor losses.

  3. Micro-scale successor: USD 0 entity revenue in 2022, c.14 employees in 2023, and the CEO's own identification of fundraising as a major challenge point to fragility.

Catalysts and monitorables (next 12 months)

  • Any Companies House restoration application for 04358718 (possible within six years of dissolution if assets or claims emerge).

  • BCL2020 Ltd filings (accounts, charges, funding rounds) and product/distribution announcements under the biocleave brand.

  • Licensing or sale of legacy Green Biologics/CLEAVE™ patents.

  • Activity in UK bio-ABE and Clostridium peers (e.g., Celtic Renewables, CHAIN Biotechnology) that might seek legacy IP.

Analyst verdict

Green Biologics Limited should be removed from any "public company" coverage list: it was never listed and, as of 16 December 2025, no longer exists as a legal entity. Its history is nonetheless instructive as a case study in industrial-biotech commercialisation. Technically, the company succeeded where many peers did not. It modernised a century-old Clostridium fermentation, retrofitted a working Minnesota ethanol plant, achieved commercial shipments by December 2016, secured federal bio-based certifications, and placed bio-acetone into a mass retail channel through Sally Beauty's 3,000-plus stores. Commercially, it failed on the one variable that matters most in commodity chemicals: cost. Oxo-butanol and phenol-co-product acetone are made in integrated, depreciated, world-scale complexes; a single corn-based fermentation plant could not match them, and the consumer premium niches GBL cultivated were too small to absorb a 21-million-gallon-equivalent asset's output. The sequential exit of every venture director between October 2018 and January 2019 was the leading indicator; the July 2019 announcement that funding could not be secured was the inevitable outcome.

The 2019–2023 Biocleave pivot was rational — redeploying genome-editing IP into low-volume, high-value recombinant proteins where Clostridium's endotoxin-free profile is an advantage — but the legal entity itself became a shell with nil revenue and minimal cash, and the operating business appears to have moved to BCL2020 Ltd before the old company was renamed back and struck off. For counterparties, the practical implications are: any contracts, IP assignments or claims must be traced to the successor or, for dissolved-company assets, to the Crown (bona vacantia) unless restored. For investors, there is no exposure to price. For strategists, the lesson is that drop-in bio-chemicals need either structural cost parity or locked-in offtake at a premium before committing to commodity-scale capacity. Overall verdict: entity dissolved — not investable; monitor successor only.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBirth (month/year)Background

Sean George Cronin Sutcliffe

Director; long-time CEO of Green Biologics

29 Apr 2008

Dec 1963

Led the company through its financing, US acquisition and commercialisation phases (CEO per Unquote, 2015)

Dr Elizabeth Rachael (Liz) Jenkinson

Director; CEO of Biocleave

26 Sep 2019

May 1980

Joined GBL as a bench scientist and rose to CTO responsible for UK R&D labs; became Chief Executive on the 2019 pivot (Microbiology Society)

Karen Elizabeth Stanley

Director

26 Sep 2019

May 1967

Background not publicly detailed in sources reviewed

Executive Leadership Team

NameAffiliation (where evident)AppointedResigned

Dr Edward McConachie Green

Founder; later founder/CEO of CHAIN Biotechnology (2014)

25 Jan 2003

29 Nov 2013

Dr Edward Timothy Davies

Early director (US-resident)

11 Oct 2003

13 Dec 2010

Simon Jones

Director

1 May 2005

10 Apr 2006

Dr Andrew George Rickman

Director/chair-level investor (role not specified)

30 Aug 2006

29 Nov 2013

Dr Victor Christou

Director (two terms)

27 Sep 2007 / 15 Dec 2010

11 May 2009 / 19 Sep 2012

Gerald Chan

Morningside

4 Feb 2009

16 Jun 2010

Dr Simon Turner

Director

22 Apr 2009

15 Dec 2010

Dr John Richard Marsh

Oxford Capital address

20 May 2009

18 Mar 2010

David John Brister

Oxford Capital Partners

1 Jun 2010

1 Nov 2018

Claude Stoufs

Capricorn Venture Partners

1 Jun 2010

10 Oct 2018

Reenie (Irene) McCarthy

Morningside address

16 Jun 2010

29 Nov 2013

Thomas James Grote

Chief Financial Officer

1 Jan 2012

15 Jul 2015

Joel Arthur Stone

President, Green Biologics Inc.

1 Jan 2012

29 Nov 2013

Simon Iliff Mansfield

Director

20 Mar 2013

12 Jul 2017

Denis Jacques Lucquin

Sofinnova Partners

29 Nov 2013

10 Oct 2018

Philippe Paul Lacamp

Swire Pacific (One Pacific Place address)

29 Nov 2013

15 Jul 2015

James Joseph Hohman

Director (US)

1 Feb 2015

20 Jun 2019

Man Ching Maggie Leung

Swire Pacific

15 Jul 2015

1 Jan 2019

Mark Noel Witt

Director (Houston, TX)

15 Jul 2015

14 Jul 2016

Martin Incledon Blair

Director

1 Jan 2018

20 Jun 2019

Brad Pritchard

Director (US)

10 Oct 2018

26 Sep 2019

Keon Alexander Reed

Director (US)

10 Oct 2018

26 Sep 2019

John Bruce Rae-Smith

Director

1 Nov 2018

26 Sep 2019

Martin Cubbon

Director (Isle of Man)

1 Nov 2018

26 Sep 2019

Paul Robert Henson

Director

1 Jan 2019

26 Sep 2019

Tamsin Denise Crane

Director

26 Sep 2019

14 Dec 2020

Executive Leadership Team — David Anderson

NameTitleSource

David Anderson

Global Vice President of Marketing

Sofinnova/Happi press releases, 2016–2018

Joel Stone

President, Green Biologics Inc. (2013)

St. Cloud Times

Dr Liz Jenkinson

Chief Technology Officer (pre-2019)

Microbiology Society

Competitive Landscape

Competitors by Segment

Business lineCompetitorTypePositioning vs GBL

Petro n-butanol (oxo)

BASF

Integrated petrochemical major

Massive scale, low-cost oxo process; price-setter

Petro n-butanol (oxo)

Dow

Integrated major

Scale and integration advantage

Petro n-butanol (oxo)

OQ Chemicals (formerly Oxea)

Oxo specialist

Cost leadership in oxo alcohols

Petro n-butanol/acetone

Eastman Chemical

Specialty/integrated

Broad solvent portfolio

Petro acetone (cumene/phenol co-product)

INEOS Phenol

Phenol/acetone leader

By-product economics make acetone structurally cheap

Bio-butanol / isobutanol

Gevo

Listed renewable fuels/chemicals developer

Also retrofitted a Minnesota ethanol plant (Luverne); pivoted to fuels

Bio-butanol

Butamax (BP/DuPont JV)

Corporate JV

Isobutanol fuel focus; IP disputes with Gevo

Bio-ABE

Celtic Renewables (Scotland)

Private

ABE from whisky by-products; closest UK peer

Bio-butanol

Cobalt Technologies

Private (historic)

Earlier US bio-butanol developer

Clostridium technology

CHAIN Biotechnology

Private (founded by GBL founder)

Clostridium for healthcare products

Protein expression (Biocleave)

Thermo Fisher, GenScript, Lonza and E. coli/yeast CROs

Large tools/CRO players

Scale and breadth; Biocleave differentiates on endotoxin-free, toxin-tolerant host

Company Snapshot

2003

Founded

Wargrave, United Kingdom

Headquarters

SWOT Analysis

Strengths

  • Commercial-scale proof: commercial shipments of n-butanol and acetone from Little Falls began in December 2016 (Chemical Engineering).
  • Proprietary genome editing: patented CRISPR-based CLEAVE™ for stable Clostridium edits (The Microbiologist).
  • Capital-light asset entry: acquired an existing 21 MMgy ethanol plant rather than building greenfield (Ethanol Magazine, 2019).
  • Certifications: USDA BioPreferred and USDA Certified Biobased; Kosher and Halal (Happi 2016/2017; Owler register).
  • Blue-chip investor syndicate: Sofinnova, Swire Pacific, Capricorn, Oxford Capital, Morningside; over USD 100M raised 2013–2015 (Business Magazine).
  • Consumer-brand partnerships: Sally Beauty (3,000+ stores), Kingsford, Kreussler in 2018 (Sofinnova release; Biofuels Digest).

Weaknesses

  • Cost disadvantage: could not compete with petrochemical processes on cost (The Chemical Engineer, 2019).
  • Single-plant concentration: all production at Little Falls; its closure ended product revenue (Biofuels Digest, Jul 2019).
  • Funding dependence: board concluded it could not secure funding to reach cash break-even (company statement, Jul 2019).
  • Governance instability: 32 officer resignations over the company's life; near-complete board turnover Oct 2018 – Sep 2019 (Companies House).
  • Sub-scale post-pivot: entity reported USD 0 revenue and c.USD 33K negative EBITDA in 2022 (Preqin).
  • Small headcount: 14 employees as of 2023 (PitchBook), limiting commercial reach of the Biocleave business.

Opportunities

  • Endotoxin-free expression: endotoxin below 0.005 EU/µg is attractive for immunology and toxicology reagents (The Microbiologist).
  • Toxin-tolerant host: expression of proteins toxic to E. coli opens toxin-fragment and vaccine-antigen niches (The Microbiologist).
  • Membrane proteins: KTP with Aston targets commercially scarce membrane-associated proteins (Aston job description).
  • Natural personal care: demand for plant-derived formulations that motivated the 2018 nail-care launch (CosmeticsDesign).
  • UK bio-economy policy: LBNet named n-butanol among biochemicals primed for UK scale-up (The Chemical Engineer).
  • IP licensing: strain and process IP could be licensed to ABE players (e.g., UK peers) — not evidenced as executed.

Threats

  • Petrochemical price-setting in butanol and acetone (structural; The Chemical Engineer).
  • Investor withdrawal: VC directors from Sofinnova, Capricorn, Oxford Capital and Swire all resigned Oct 2018 – Jan 2019 (Companies House).
  • Feedstock risk: reliance on US-grown corn as primary feedstock (2018 press release).
  • Fundraising difficulty in the pivot era, identified by the CEO as among the biggest challenges (Microbiology Society, 2020).
  • Large incumbents in protein expression (Thermo Fisher, GenScript, Lonza).
  • Legal dissolution: the entity no longer exists; any residual rights or claims vest per UK rules on dissolved companies (Companies House, Dec 2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Dec 2025Dissolved via voluntary strike-off (Final Gazette)Legal end of the entity
30 Sep 2025First Gazette notice for voluntary strike-offTwo-month objection window opened
22 Sep 2025DS01 strike-off application filedDirectors' decision to close entity
10 Jul 2025Total exemption full accounts to 30 Jun 2025 filedFinal financial statements
3 Mar 2025Confirmation statement (23 Jan 2025), no updatesRoutine compliance
1 Nov 2024Accounts to 30 Jun 2024 filedRoutine
29 Mar 2024Accounts to 30 Jun 2023 filedRoutine
13 Mar 2024Registered office moved to Wargrave, BerkshireExit from Milton Park; shell status
5 Feb 2024Confirmation statement with updates–
14 Aug 2023Renamed from Biocleave Limited to Green Biologics LimitedFrees the "Biocleave" name for successor; legacy entity becomes non-trading
12 Apr 2023Accounts to 30 Jun 2022 filedFY2022 loss c.GBP 25K (Craft)
6 Jul 2022Accounts to 30 Jun 2021 filedRoutine
17 Sep 2021Group accounts to 30 Jun 2020 filedLast group accounts
14 Dec 2020Director Tamsin Crane resignsBoard slimmed to three
Oct 2020CEO Liz Jenkinson interview describing pivot and fundraising challengesPublic articulation of Biocleave strategy
2020Biocleave operating business formed; protein expression products launchedPivot execution
3 Jul 2020Group accounts to 30 Jun 2019 filedCovers closure year
25 Oct 2019Renamed Biocleave LimitedStrategic pivot
26 Sep 2019Board reset and share cancellationRecapitalisation
26 Aug 2019Senior convertible loan approvedBridge financing
14–16 Jul 2019Closure of Little Falls plant and US wind-down announcedFailure of commercial model
20 Jun 2019Directors Blair and Hohman resignPre-closure governance change
1 Jan 2019Swire Pacific director Maggie Leung resignsInvestor exit signal
1 Nov 2018Oxford Capital director resigns; Rae-Smith and Cubbon joinBoard restructuring
10 Oct 2018Sofinnova and Capricorn directors resign; Pritchard and Reed joinInvestor exit signal
25 Jun 2018Bio-acetone nail polish remover launched with Sally Beauty/MariannaConsumer launch
Apr 2018Kreussler dry-cleaning solvent agreementNiche market entry
Jan–Mar 2018EcoLight lighter fluid with KingsfordConsumer launch
2018Global Cleantech 100 listingExternal validation
Dec 2016First commercial shipments from Little FallsCommercialisation milestone

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

4 charts
Income Statement: Operating income / EBIT was GBP -0 Mn in FY2022.
Green Biologics Limited — Income Statement
Series (GBP Mn)FY2022
Operating income / EBIT-0
Net income-0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. UK Companies House — GREEN BIOLOGICS LIMITED (04358718): overview, filing history, officers. (find-and-update.company-information.service.gov.uk)
  2. Biofuels Digest, "Green Biologics closes Minnesota butanol and acetone plant", 14 Jul 2019. (biofuelsdigest.com)
  3. Ethanol/Biodiesel Magazine, "Green Biologics to cease operations", 16 Jul 2019. (biodieselmagazine.com)
  4. Bioenergy International, "Green Biologics to shutter US biochemical plant", 2019. (bioenergyinternational.com)
  5. The Chemical Engineer, "Green Biologics closes biochemicals plant in US", 2019. (thechemicalengineer.com)
  6. Chemical Engineering, "Green Biologics begins commercial shipment of bio-based n-butanol and acetone", 2016. (chemengonline.com)
  7. Happi, "Green Biologics ships bio-based n-butanol and acetone", Dec 2016 / Feb 2017. (happi.com)
  8. Advanced BioFuels USA (St. Cloud Times), "Ohio Firm Will Buy Little Falls Ethanol Plant", 12 Sep 2013. (advancedbiofuelsusa.info)
  9. Albert Lea Tribune, "Shareholders approve ethanol cooperative sale in Little Falls", 4 Dec 2013. (albertleatribune.com)
  10. Brainerd Dispatch, "Central MN Ethanol Co-op closes sale of ethanol plant to Green Biologics", Dec 2014. (brainerddispatch.com)
  11. Business Magazine, "Abingdon: Green Biologics secures $76m in debt and equity financing", 2015. (businessmag.co.uk)
  12. Unquote, "Sofinnova et al invest USD42m in Green Biologics", 2015. (unquote.com)
  13. Sofinnova Partners, press release on bio-based acetone nail polish remover, 25 Jun 2018. (sofinnovapartners.com)
  14. CosmeticsDesign, Green Biologics / Marianna / Sally Beauty, 27 Jun 2018. (cosmeticsdesign.com)
  15. Owler, Green Biologics news register. (owler.com)
  16. Microbiology Society, "An interview with Dr Liz Jenkinson", Oct 2020. (microbiologysociety.org)
  17. The Microbiologist, "How Biocleave is teaching Clostridium new tricks in protein recombination". (the-microbiologist.com)
  18. Advanced Oxford, Biocleave (formerly Green Biologics Ltd.) profile. (advancedoxford.com)
  19. Aston University, KTP Associate job description (BCL2020 Ltd trading as biocleave). (jobs.aston.ac.uk)
  20. Harper James, "Developing terms and distribution agreements for Biocleave". (harperjames.co.uk)
  21. South Coast Biosciences DTP, Biocleave placement. (southcoastbiosciencesdtp.ac.uk)
  22. MarketScreener, Edward M. Green profile. (marketscreener.com)
  23. Preqin, Green Biologics Limited profile. (preqin.com)
  24. Craft, Biocleave profile. (craft.co)
  25. PitchBook, Green Biologics profile. (pitchbook.com)
  26. CB Insights, Green Biologics. (cbinsights.com)
  27. StartupBlink (Crunchbase data), Green Biologics. (startupblink.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.